4MARION PL, SALAZAR FH, WINTERS MA, etal. Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication [ J]. Antimicrob Agents Chemother, 2002,46 ( 1 ) .. 82-88.
5ONO SK, KATO N, SHIRATORI y, et al. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance [J]. J Clin Invest, 2001, 107(4) :449-455.
6JULANDER JG, COLONNO RJ, SIDWELL RW, et al. Characterization of antiviral activity of entecavir in transgenic mice expressing hepatitis B virus [J]. Antiviral Res, 2003, 59(3):155-161.
7COLONNO ILI, GENOVESI EV, MEDINA I, et al. Long-term entecavir treaUnent results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection [J].J Infect Dis, 2001, 184(10): 1236-1245.
8de MAN B.A, WOLTERS LM, NEVENS F, etal. Safety and efficacy of oral Entecavir given for 28 days in patients with chronic hepatitis B virus infection [J]. Hepatology, 2001,34(3) :578-582.
9LAI CL, ROSMAWATI M, LAO J, etal. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection [ J ]. Gastroenterology, 2002, 123 ( 6 ) :1831-1838.
10HONKOOP P, de MAN RA. Entecavir: a potent new antiviral drug for hepatitis B [J]. Expert Opin Investig Drugs, 2003,12(4) :683-688.
1Ramsoekh D, Taimr P, Vanwolleghem T, et al. Reversible severe hepatitis in anorexia nervosa: A case report and overview[J]. Eur J Gastroenterol Hepatol, 2014, 26(4): 473-477.
2He B, Zhang Y, L ti MH, et al. Glucocorticoids can increase the survival rate of patients with severe viral hepatitis B: A meta-analysis[J]. Eur J Gastroenterol Hepatol, 2013, 25(8): 926-934.
